Web31 dec. 2024 · Lyell successfully completed its initial public offering in June 2024 with net proceeds of $391.8 million. Based on the current operating plan, Lyell believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2025. About Lyell Immunopharma, Inc. Web12 mai 2024 · Vice President, Investor Relations - USA (510) 713-5568 Nicole Kenyon Head of Global Corporate & Employee Communications - USA (510) 988-8553 Ben Starkie Corporate Communications - Europe +41 (0) 79-292-3499 Source: Logitech International. Multimedia Files: Logitech_Logo.jpg 1000 x 500 jpg 17 KB.
Lyell Immunopharma and PACT Pharma Announce Research and …
Web企查查为您提供Lyell Immunopharma, Inc.的最新工商信息、公司简介、公司地址、电话号码、招聘信息、信用信息、财务信息、法律诉讼等多维度详细信息查询,让您对Lyell Immunopharma, Inc.能够做到全面的了解! WebFind the latest Financials data for Lyell Immunopharma, Inc. Common Stock (LYEL) at Nasdaq.com. mass wealth radio
Lyell Immunopharma Reports Business Highlights and Financial …
Web16 nov. 2024 · Lyell Immunopharma has a market capitalization of US$2.7b, so we would expect some institutional investors to have noticed the stock. Our analysis of the ownership of the company, below, shows ... Web17 iun. 2024 · About Lyell Immunopharma, Inc. ... Head of Investor Relations [email protected]. Related Quotes. Symbol Last Price Change ... Nine investors put in a … Web17 iun. 2024 · Lyell Immunopharma, a T-cell reprogramming company, has raised about $425 million for its IPO after pricing its 25 million shares at $17 per share. The stock began trading June 17, 2024 on the NASDAQ under the ticker symbol “LYEL.” ... Investor Relations, Marketing & Communications Forum. April 19-20, 2024 Convene, 117 W 46th … massway supermarket logo